Tumefactive demyelination presenting during bevacizumab treatment

We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

Saved in:
Bibliographic Details
Published in:BMJ case reports 2015-12, Vol.2015, p.bcr2015212173
Main Authors: Rice, Claire M, Rossiter, David, Fehmi, Janev, Stevens, James C, Renowden, Shelley A, Cohen, Nicki, Bailey, Clare, Scolding, Neil J
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - adverse effects
Bevacizumab - administration & dosage
Bevacizumab - adverse effects
Biopsy
Child
Choroidal Neovascularization - pathology
Clinical trials
Demyelinating Diseases - cerebrospinal fluid
Demyelinating Diseases - chemically induced
Demyelinating Diseases - pathology
Edema
Europe (West)
Female
Follow-Up Studies
Humans
Immunotherapy
Intravitreal Injections
Monoclonal antibodies
Multiple sclerosis
Treatment Outcome
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Vascular endothelial growth factor
Visual acuity
White
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2015-212173